OncoImmunity is a cutting-edge startup based in Oslo, Norway, specializing in the use of artificial intelligence (AI) to enhance cancer immunotherapy. The company develops innovative software solutions aimed at guiding the discovery of neoantigen-based personalized immunotherapies and biomarkers. Neoantigens are unique markers found on cancer cells that can be targeted by the immune system, making treatments more effective and personalized.

OncoImmunity primarily serves clients involved in immuno-oncology clinical trials, including pharmaceutical companies, research institutions, and healthcare providers. The market it operates in is the rapidly growing field of cancer immunotherapy, which focuses on harnessing the body's immune system to fight cancer.

The business model of OncoImmunity revolves around the development and licensing of its proprietary AI-driven software. This software uses machine learning algorithms to predict antigen presentation and immunogenicity, which helps in selecting patient-specific targets for immunotherapy. By providing these advanced predictive tools, OncoImmunity enables its clients to design more effective and personalized cancer treatments, thereby increasing the success rates of clinical trials.

OncoImmunity generates revenue through licensing fees for its software solutions, as well as through partnerships and collaborations with other companies and research organizations. For instance, the company has partnered with the NEC Group and CEPI to develop AI-designed vaccines and other therapeutic solutions.

In summary, OncoImmunity leverages advanced AI technology to revolutionize cancer treatment, focusing on personalized immunotherapies that improve clinical trial outcomes. Its innovative approach and strategic partnerships position it as a key player in the immuno-oncology market.

Keywords: Cancer, Immunotherapy, Artificial Intelligence, Neoantigens, Personalized Medicine, Clinical Trials, Machine Learning, Biotechnology, Healthcare, Software Solutions.